Transatlantic Alliance

We take a look at how MorphoSys US Inc. is preparing for the potential tafasitamab launch. Tafasitamab is MorphoSys’ first proprietary drug candidate currently under FDA-priority review for approval to treat an especially difficult form of diffuse large B cell lymphoma. In January 2020, the company signed a partnering deal with Incyte that will support MorphoSys to achieve its next goal – to co-commercialize tafasitamab in the United States

Transatlantic Alliance

We take a look at how MorphoSys US Inc. is preparing for the potential tafasitamab launch. Tafasitamab is MorphoSys’ first proprietary drug candidate currently under FDA-priority review for approval to treat an especially difficult form of diffuse large B cell lymphoma. In January 2020, the company signed a partnering deal with Incyte that will support MorphoSys to achieve its next goal – to co-commercialize tafasitamab in the United States

MorphoSys is currently waiting for the potential approval of its lymphoma drug candidate, tafasitamab. The company and its U.S. partner Incyte have signed a collaboration and licensing agreement for the global development for tafasitamab aiming to work together towards the shared ambition – to deliver tafasitamab to patients.

Recognizing the benefits of establishing a U.S. presence while gearing up towards the expected launch of tafasitamab, MorphoSys’ management team started to set-up its subsidiary in the U.S. as early as July 2018.

Over the course of 2019, the company made great strides in establishing the required commercial infrastructure and hiring the right talent for the potential tafasitamab launch. With new CEO Dr. Jean-Paul Kress splitting his time between both Boston and Planegg, the team has layed the groundwork to become a successful fully integrated biopharmaceutical company.

(01) Dr. Nuwan Kurukulasuriya, Senior Vice President and Head of Medical Affairs (02) Insight into the Boston office

Boston came as no surprise

MorphoSys planted its flag in Boston. Located in a brick red high-rise with green-tinted windows overlooking the city’s harbor, MorphoSys US Inc. is in the middle of one of the most important life science hubs worldwide. MorphoSys’ decision on Boston, Massachusetts, as the location for its U.S. presence is not surprising. With its world-class universities such as Harvard, MIT and Boston University only a short ride away and a number of world-renowned hospitals serving as a repository for biotech innovation and talent, Boston is considered to be the cradle of biotech in the U.S., and, thus, is the ideal location for MorphoSys’ U.S. operations.

But selecting the location for the company’s U.S. presence was only the beginning. The next challenge was the task of hiring employees. Because MorphoSys believes its most precious resource are its people, their values and their networks of influence, talent acquisition was a top priority. MorphoSys successfully added nearly 40 full-time U.S. team members in 2019, and plans to continue hiring, aiming to increase the number to over 150 employees by mid-2020.

The MorphoSys U.S. team is comprised of professionals from many different disciplines and is prepared to reach out to all critical stakeholders including patients, healthcare providers, payers, policy makers and patient advocacy organizations.

Representing the talented group of professionals that have become a part of the MorphoSys family in the U.S., David Trexler, President of MorphoSys US Inc., and Dr. Nuwan Kurukulasuriya, Senior Vice President and Head of Medical Affairs, both seasoned industry experts, commented on the progress and the importance of transatlantic collaboration on the way to bringing tafasitamab to patients in need.

(03) Insight into the Boston office (04) David Trexler, President of MorphoSys US Inc., with the U.S. team

Ensuring close collaboration and optimal communication, all team members on both sides of the Atlantic, in the Planegg, Germany headquarters and the U.S. office in Boston, will continue to support each other to ensure smooth preparatory work for the planned tafasitamab launch.

“The team we are building is a testament to the extraordinary pool of talent in the U.S. biotech space. It is this dynamic and highly performing team that embodies the spirit of MorphoSys and shares our company values of innovation, courage, collaboration and urgency,” David Trexler said.

“MorphoSys is a very special place,” added Dr. Nuwan Kurukulasuriya. “Both in Planegg and in Boston, it brings together like-minded individuals committed towards the common goal of improving the lives of patients suffering from serious diseases.”

Potentially changing the treatment paradigm in lymphoma

To position itself in the hematology-oncology community, MorphoSys wants to accomplish more than informing doctors about its own clinical data. Complementing the data from its L-MIND study of tafasitamab in combination with lenalidomide, the company has also gathered real world data of patients who have been treated with a lenalidomide monotherapy. Moreover, MorphoSys initiated the clinical development of tafasitamab in firstline DLBCL, combining tafasitamab with the current standard of care, R-CHOP. These data will provide additional evidence to the lymphoma community and highlights MorphoSys’ commitment to further research in the space.

MorphoSys considers tafasitamab to be a “pipeline in a product”. Its opportunities both within and beyond the non-Hodgkin lymphoma space are numerous. These opportunities encompass not only additional treatment lines, but also arise for several other indications. And MorphoSys is ideally poised to unlock the greater value of tafasitamab – both through its own industry leadership and scientific excellence and through marrying resources with Incyte, a partner with great expertise in the hemato-oncology space and proven commercial capabilities. Having signed a global licensing deal recently, both companies will now join forces to realize the full value proposition of tafasitamab.

Ensuring close collaboration and optimal communication, all team members on both sides of the Atlantic, in the Planegg, Germany headquarters and the U.S. office in Boston, will continue to support each other to ensure smooth preparatory work for the planned tafasitamab launch.